Finance

Lists
NUVB:NYSE
Nuvation Bio Inc
$6.52
-1.36%
(-0.090) 1D
$6.56
+0.60% (+0.039)
After hours
Closed: Sep 9, 4:00:09 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NUVB...
Open
$6.55
High
$6.72
Low
$6.50
Mkt. cap
2.29B
Avg. vol.
5.33M
Volume
0.00
52-wk high
$9.75
52-wk low
$2.99
EPS
-$0.44
Beta
1.52
Shares outstanding
351.12M
No. of employees
305
Open
$6.55
High
$6.72
Low
$6.50
Mkt. cap
2.29B
Avg. vol.
5.33M
Volume
0.00
52-wk high
$9.75
52-wk low
$2.99
EPS
-$0.44
Beta
1.52
Shares outstanding
351.12M
No. of employees
305
News stories
From web sources and news partners
About Nuvation Bio Inc
CEODavid Hung
Employees305
Founded2018
Headquarters-
SectorPharmaceutical industry
Websitenuvationbio.com
Analyst ratings
Based on 8 analysts giving stock ratings to NUVB in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for NUVB in the last 3 months.
Highest
Current $6.52
$21.00 (+222.09%)
Average
$14.50 (+122.39%)
Lowest
$11.00 (+68.71%)
Analyst
Recommendation
Action
Price target
Projected
Date
Li Watsek
Cantor Fitzgerald
Buy
Initiated
$12.00
+84%
08/21/2026
Priyanka Grover
J.P. Morgan
Buy
Initiated
$13.00
+99.4%
08/18/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$14.00
+114.7%
08/07/2026
Gregory Renza
Truist Financial
Buy
Maintained
$13.00
+99.4%
08/07/2026
Leonid Timashev
RBC Capital
Buy
Reiterated
$20.00
+206.7%
08/06/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$21.00
+222.1%
08/07/2026
Boris Peaker
JonesTrading
Buy
Reiterated
$12.00
+84%
08/06/2026
David Nierengarten
Wedbush
Buy
Maintained
$11.00
+68.7%
07/21/2026
Yaron Werber
TD Cowen
Buy
Reiterated
-
-
06/01/2026
Soumit Roy
JonesTrading
Buy
Maintained
$12.00
+84%
04/06/2026
Michael Yee
UBS
Hold
Maintained
$7.00
+7.4%
03/03/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.15 / -$0.12
-25.15%miss
Revenue / Est. (USD)
31.69M / 28.70M
+10.42%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
13.12M
41.86M
83.23M
31.69M
Cost of goods sold
3.35M
1.28M
5.99M
9.47M
Cost of revenue
3.35M
1.28M
5.99M
9.47M
Research and development expenses
28.85M
34.30M
35.05M
30.66M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
37.36M
40.33M
38.31M
42.59M
Operating expense
66.20M
74.62M
73.36M
73.25M
Total operating expenses
69.55M
75.90M
79.35M
82.72M
Operating income
-56.43M
-34.04M
3.88M
-51.04M
Other non operating income
1.14M
-1.18M
3.11M
-179.00K
EBT including unusual items
-55.79M
-36.59M
5.40M
-62.84M
EBT excluding unusual items
-55.80M
-36.59M
5.39M
-53.38M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-55.79M
-36.59M
5.40M
-62.84M
Net profit margin
-425.24%
-87.40%
6.48%
-198.31%
Earnings per share
-0.14
-0.09
0.04
-0.15
Interest and investment income
6.03M
5.30M
5.11M
4.60M
Interest expense
-6.53M
-6.67M
-6.71M
-6.76M
Net interest expenses
-501.00K
-1.38M
-1.60M
-2.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
-55.90M
-33.50M
4.42M
-50.50M
Gain or loss from assets sale
-4.00K
3.00K
-
-1.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps